Compare Johnson & Johnson (JNJ) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Shell PLC — how do they compare? Johnson & Johnson trades at $249.38 (market cap $598.96B), while Shell PLC trades at $86.98 (market cap $235.24B). The key difference: Johnson & Johnson is far larger — about 2.5× Shell PLC's market cap, and Shell PLC pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| JNJ | SHEL | |
|---|---|---|
Market Cap | $598.96B | $235.24B |
Volume | 6,156,228 | — |
Sector | Health | Energy |
52-Week High | $267.24 | $94.15 |
52-Week Low | $164.36 | $70.31 |
Enterprise Value | $631.90B | $287.77B |
Dividend Yield | 2.15% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Shell (SHEL) trades at $86.20, down 1.28% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company maintains solid fundamentals with a P/E of 13.6 and net income margin of 7.01%, though revenue has declined from $381.3B in 2022 to $266.9B in 2025. Recent developments include expansion in Caribbean LNG infrastructure and the pending $16.4B acquisition of ARC Resources, positioning for strategic growth despite Middle East production disruptions.
Outlook remains positive with analyst consensus at Buy (69%) and $114.13 price target, representing 32% upside. Key risks include geopolitical volatility affecting oil prices and ongoing production challenges. The stock offers value through discounted valuation metrics and dividend yield, though investors should monitor execution on growth initiatives and energy market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
